GLI1 and cancer: In B-cell ALL, cancer stem cells that were treated with a Smo inhibitor showed decreased self-renewal potential (91), a result mirrored by the subset of GLI1 rich T-cells when they were treated with either a GLI or SMO inhibitor (92).